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Results.
Inhibition of Ca v 3.3 currents by poly-unsaturated amino-acids.
We have characterized the effects of lipoamino-acids on the Ca v 3.3 current because among lipids inhibiting T-currents, only this class showed a higher T-type specificity, with no effect on cannabinoid receptors and TRPV1 (Barbara et al., 2009; Bradshaw and Walker, 2005; Huang et al., 2001) . We found that the Ca v 3.3 current was strongly inhibited by 3 µM N-docosahexaenoyl glycine (chain length 22 carbons, 6 doubles bonds, 22:6 Gly) at a holding potential (HP) of -75 mV (Fig. 1A) but not at HP -110 mV (Fig. 1B) . The inhibition occurred in the minute range and was relieved by application of 3 mg/ml bovine serum albumin (Barbara et al., 2009; Gilmore et al., 2012) (BSA, Fig. 1C ). The extent of inhibition increased gradually with the number of double bonds in the N-acyl glycine (Fig. 1E) . The saturated Narachidoyl glycine (20:0 Gly) produced weak inhibition (~13 %, n=5, Fig. 1D-E) , N-linoleoyl glycine (18:2 Gly) produced ~50 % inhibition (n=7, Fig. 1E, p≤0 .001 compared to 20:0 Gly), N-arachidonoyl glycine (20:4, NAGly) produced ~67 % inhibition (n=11, Fig. 1E, p≤0 .05 compared to 18:2 Gly) and the fully poly-unsaturated 22:6 glycine produced ~74 % inhibition (n=12, Fig. 1E , non-significant compared to 20:4 Gly). Interestingly, the increase in the number of double bonds in fatty acids augments the membrane fluidity whereas it restricts the conformational freedom of the molecule possibly leading to the adequate conformation to inhibit T-current. The Ca v 3.3 current was also inhibited by several N-arachidonoyl aminoacids including N-arachidonoyl-3-OH-γ-butyric acid (NAGABA-OH, ~81 % inhibition (n=22)), N-arachidonoyl-γ-butyric acid (NAGABA, ~59 % inhibition (n=24)), Narachidonoyl-L-serine (NASer, ~64 % inhibition (n=22)) and N-arachidonoyl alanine (NAAla, ~45 % inhibition (n=23, Fig. 1E) ). In addition, the lipo-neurotransmitters N-arachidonoyl taurine (NATau), N-arachidonoyl serotonin (NA-5HT) and N-arachidonoyl dopamine (NADA) inhibited the Ca v 3.3 current by ~74 %, ~34 % and ~20 %, respectively ( Fig. 1E , 1 1 n≥8). Similar findings were obtained with NADA and NA-5HT using an intracellular medium containing 10 mM BAPTA (n=5) (Gilmore et al., 2012; Ross et al., 2009) as well as on Ca v 3.1 and Ca v 3.2 current (data not shown). Application of 3 µM NADA induced ~18 % inhibition of the Ca v 3.1 current (n=5) and ~27 % inhibition of the Ca v 3.2 current (n=6).
Similarly, application of 3 µM NA-5HT induced ~44 % inhibition of the Ca v 3.1 current (n=16) and ~50 % inhibition of the Ca v 3.2 current (n=14). As previously described (Chemin et al., 2001) , in these experiments, 3 µM NAEA strongly inhibited the three Ca v 3 currents by ~74-80 % (n≥8, Fig. 1E ).
NAGly effect on Ca v 3.3 biophysical properties.
NAGly inhibited the Ca v 3.3 current at every potential with inhibition of the peak current at -35 mV by ~40 % with 1 µM NAGly and by ~70 % with 3 µM NAGly ( Fig. 2A) .
NAGly had weak and not significant effect on the Ca v 3.3 current-voltage relationship since the V 0.5 values were -45.7 ± 1.3 mV (n=8) in control condition, -49.6 ± 1.4 mV (n=8) during 1 µM NAGly application and -48.6 ± 0.8 mV (n=5) during 3 µM NAGly application (p>0.05).
We also observed that 3 µM NAGly accelerated the inactivation rate of Ca v 3.3 current at every tested potential (p<0.05, n=5, Fig. 2B ) without significant corresponding effect on the activation rate ( Fig. 2C ). Furthermore, NAGly induced a ~10 mV negative shift in the steadystate inactivation properties of Ca v 3.3 (Fig. 2D ). The V 0.5 values were -73.1 ± 0.9 mV (n=8) in control condition, -80.6 ± 1.07 mV (p<0.001, n=8) during 1 µM NAGly application and -83.2 ± 0.8 mV (p<0.001, n=7) during 3 µM NAGly application. Application of 3 µM NAGly also decreased the slope factor of the steady-state inactivation curve of Ca v 3.3 from 5.2 ± 0.2 in control condition to 4.3 ± 0.2 (p<0.05). We next investigated the effect of NAGly on the recovery from inactivation of Ca v 3.3 current ( Fig. 2E ). The recovery from inactivation of Ca v 3.3 current was well fit by a mono-exponential revealing that NAGly strongly increased
MOL #89581
1 2 the τ of recovery from 298 ± 20 ms (n=8) in control condition to 453 ± 22 ms (p<0.001, n=8) during 1 µM NAGly application and to 771 ± 43 ms (p<0.001, n=8) during 3 µM NAGly application. Finally, we found that both 1 µM and 3 µM NAGly slowed the deactivation of the Ca v 3.3 current at repolarization potentials ranging from -120 to -60 mV (p<0.05, n=8, Fig.   2F ).
Pharmacological interaction of endogenous lipids and TTA-A2 on the Ca v 3.3 channel.
Recently, TTA-A2, a potent and specific synthetic inhibitor of T-current was described (Kraus et al., 2010; Reger et al., 2011; Uebele et al., 2009a; Uebele et al., 2009b) . As observed with endogenous lipids, TTA-A2 inhibited the Ca v 3 current at physiological HP but not at very negative potentials (i.e. -110 mV) (Francois et al., 2013; Kraus et al., 2010) .
Furthermore, as observed with endogenous lipids, TTA-A2 induced a negative shift in the steady-state inactivation properties of Ca v 3 current and slowed their recovery from inactivation (Francois et al., 2013; Kraus et al., 2010) . It should be noted that several other structurally-unrelated T-channel inhibitors, including mibefradil, flunarizine and pimozide, which also exhibit similar state-dependent inhibition of T-currents (Martin et al., 2000; Santi et al., 2002) , were shown to interact with [ 3 H]-TTA-A1 binding to membranes containing Ca v 3.3 (Uebele et al., 2009b) . Therefore we investigated whether endogenous lipids and TTA-A2 could share a common inhibitory mechanism on Ca v 3.3. To this purpose, the effect of NAEA (which strongly inhibited Ca v 3.3 current) and NADA or NA-5HT (which mildly inhibited Ca v 3.3 current) were compared in the presence and the absence of TTA-A2 ( Fig. 3 ).
We found that 300 nM NAEA alone induced 56 ± 2 % inhibition of the Ca v 3.3 current and accelerated the inactivation kinetic (τ) by 32.5 ± 2.6 % (p<0.05, n=8; Fig. 3A ), as previously described (Chemin et al., 2001) . Similarly, 3 nM TTA-A2 alone induced 52 ± 3 % inhibition of the Ca v 3.3 current but slowed the inactivation kinetic (τ) by 34.1 ± 5.4 % (p<0.05, n=7; 1 3 Fig. 3B ). Interestingly, when NAEA and TTA-A2 were applied simultaneously, the Ca v 3.3 current was inhibited by 70 ± 2 % (n=10; Fig. 3C ), indicating that the effect of NAEA and TTA-A2 are only partially additive ( Fig. 3G ). In this latter case, the inactivation kinetic (τ) was accelerated by 21.7 ± 4.9 % (p<0.05, n=10; Fig. 3C ). The results were not different (p>0.05) when both molecules were applied after NAEA application (n=5, Fig. 3A ) or TTA-A2 application (n=5, Fig. 3B ). These results were further confirmed using the mild inhibitors NADA and NA-5HT. Indeed, when 3 µM NA-5HT, which inhibited the Ca v 3.3 current by 20 ± 4 % (n=16; Fig. 3D ), was applied with TTA-A2, the resulting inhibition was only 33 ± 4 % (n=19; Fig. 3F ) demonstrating no additive effects. This was clearly evidenced when NA-5HT and TTA-A2 where applied together after TTA-A2 treatment (Fig. 3E ). In this case the inhibition induced by both compounds was less than those obtained with TTA-A2 alone (p<0.01, n=11, Fig. 3E and Fig. 3G ). Similar findings were obtained with 3 µM NADA (n=15, Fig. 3G ). Overall, these results demonstrated a pharmacological interaction between endogenous lipids and TTA-A2 and suggested that both molecules could share the same molecular site on the Ca v 3.3 protein.
N-acyl derivatives that inhibited Ca v 3.3 current displaced [ 3 H]-TTA-A1 binding.
Because lipids and TTA-A2 possibly act at the same molecular site, we investigated whether bio-active lipids that inhibit Ca v 3.3 current could displace [ 3 H]-TTA-A1 (a radiolabeled derivative of TTA-A2) binding to membranes containing Ca v 3.3, as demonstrated for several state-dependent T-channel antagonists (Uebele et al., 2009b) . We found that N-arachidonoyl amino-acids NASer and NAGly, which inhibited Ca v 3.3 current ( Fig. 1D ), displaced [ 3 H]-TTA-A1 binding in a concentration-dependent manner (Fig. 4A ).
The K i for NASer was 9.02 ± 0.06 µM and 7.12 ± 0.31 µM for NAGly whereas the Hill slope number (n Hill ) was 2.1 and 1.8 for NASer and NAGly, respectivelly. Displacement of [ 3 H]-1 4 TTA-A1 binding was not observed with the saturated arachidoyl glycine at concentrations up to 40 µM (20:0, Fig. 4A ). Similarly, the endocannabinoid anandamide (20:4 EA) displaced [ 3 H]-TTA-A1 binding with a K i of 1.35 ± 0.04 µM and a n Hill of 2.4, but not the saturated form, N-arachidoyl ethanolamine (Fig. 4B ). In addition, the N-arachidonoyl neurotransmitters NATau, N-arachidonoyl dopamine (NADA) and N-arachidonoyl serotonin (NA-5HT), also displaced [ 3 H]-TTA-A1 binding (Fig. 4C ). The K i was 4.13 ± 0.11 µM for NATau, 0.170 ± 0.004 µM for NADA and 0.026 ± 0.001 µM for NA-5HT whereas the n Hill was 1.5, 1.3 and 1.1 for NATau, NADA and NA-5HT, respectively.
TTA-Q4, a positive allosteric modulator of [ 3 H]-TTA-A1 binding, increased lipidinduced inhibition of Ca v 3.3 current.
The structurally distinct T-type antagonist, TTA-Q4, was shown to increase Therefore, we investigated whether TTA-Q4 had a similar effect on lipid-induced Ca v 3.3 current inhibition. We found that 20 nM TTA-Q4 alone induced 22 ± 4 % inhibition of Ca v 3.3 current (n=8, Fig. 5A ), 100 nM anandamide alone induced 18 ± 5 % inhibition (n=5, Fig. 5B) whereas application of both compounds induced 72 ± 4 % inhibition (n=7, Fig. 5C-D) , which is much greater than the anticipated sum of ~40% expected for additive effects (as indicated by an arrow in Fig. 5I ). We also found that 300 nM NA-5HT induced negligible effect on induced 72 ± 2 % inhibition of Ca v 3.3 current (n=11, Fig. 5I ). Overall, these results indicated that TTA-Q4 and poly-unsaturated lipids modulated Ca v 3.3 current in a synergistic manner.
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Discussion
In this study we demonstrated that lipid effects on Ca v 3.3 biophysical properties share many features with those induced by TTA-A2, especially regarding the "gating properties".
Importantly, inhibition of Ca v 3.3 current by both lipids and TTA-A2 occurs only at depolarized resting potentials at which Ca v 3.3 channels are partly inactivated. We also documented that endogenous lipids and TTA-A2 share similar molecular mechanisms. Firstly, we found that TTA-A2 effects on Ca v 3.3 current were weakly additive with those produced by lipids or were even decreased when both lipids and TTA-A2 were applied together. Ca v 3.1 and Ca v 3.2 currents (not shown), as previously observed with fatty acids and N-acyl ethanolamines (Chemin et al., 2007) . In contrast with previous studies (Gilmore et al., 2012; Ross et al., 2009) , we found that NA-5HT and NADA were weak inhibitors of the Ca v 3.3 currents (as well as Ca v 3.1 and Ca v 3.2 currents). Similar results were obtained using a stable HEK-293 cell line expressing Ca v 3.3 current or using an intracellular medium containing 10 mM BAPTA (Gilmore et al., 2012; Ross et al., 2009 ). We do not have yet any satisfactory explanation for this discrepancy because the Ca v 3 subunits and the lipids used here are identical and from the same companies as those previously used (Gilmore et al., 2012; Ross et al., 2009) . We also demonstrated that the inhibition occurred only at depolarized resting potentials indicating that lipids preferentially affect T-channels in the inactivated state or in intermediate closed states (Talavera et al., 2004) . Furthermore, NAGly induced a hyperpolarized shift in the Ca v 3.3 steady-state inactivation properties leading to current inhibition at physiological resting potentials. In addition, we found that NAGly slowed the recovery from inactivation of Ca v 3.3 current, a property that was not investigated before on recombinant channels. These effects on inactivation properties were reminiscent of those induced by TTA-A2, which induced similar effects on steady-state inactivation and recovery from inactivation (Francois et al., 2013; Kraus et al., 2010) . NAGly also induced a hyperpolarized shift in the steady-state inactivation of Ca v 3.1 and Ca v 3.2 currents and slowed their recovery from inactivation confirming a common biophysical mechanism (data not shown). However, NAGly had specific effects on the Ca v 3.3 current kinetics. NAGly accelerated the inactivation kinetics of Ca v 3.3 current at every tested potential without the corresponding effect on Ca v 3.1 and Ca v 3.2 currents (data not shown). In the same way,
NAGly induced a deceleration of the Ca v 3.3 deactivation kinetic, which was not observed on Ca v 3.1 and Ca v 3.2 currents (data not shown) and is not yet documented for TTA-A2.
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We found that TTA-A2 induced inhibition of Ca v 3.3 current was not fully additive with those produced by anandamide when both compounds were applied together. Moreover, the presence of NADA or NA-5HT decreased the TTA-A2 effect, probably because they did not produce an important inhibition per-se, suggesting that they could share with TTA-A2 a common site on Ca v 3.3. This was confirmed using [ 3 H]-TTA-A1, a radioactive derivative of TTA-A2, which specifically binds membranes expressing Ca v 3.3 (Uebele et al., 2009b) .
Indeed, we demonstrated that poly-unsaturated lipids NAGly, NASer, NAEA, NADA, NA-5HT and NATau, all displaced the [ 3 H]-TTA-A1 binding with K i in a micromolar or submicromolar range whereas saturated lipids (which did not inhibit Ca v 3.3 current) had no effect. The affinity (K i in µM) obtained with poly-unsaturated lipids were NA-5HT (0.02) < NADA (0.17) < NAEA (1.35) < NATau (4.13) < NAGly (7.12) < NASer (9.02). These findings are in good agreement with our electrophysiological studies on Ca v 3.3 current inhibition. Interestingly, we also found that NADA and NA-5HT, which had mild effect on Ca v 3.3 current, strongly bound to Ca v 3.3 expressing membranes. Accordingly, the presence of NADA or NA-5HT prevented TTA-A2 inhibitory effects in electrophysiological experiments.
We have previously shown that inhibitory effects of lipids on T-current depend on both the amide and the hydroxyl groups (Chemin et al., 2007) . In this context, the aromatic heterocyclic rings of NADA and NA-5HT, which increase the distance between the amide and the hydroxyl groups and are also hydrophobic, could impair interaction with key amino-acids in the Ca v 3.3 protein and therefore their inhibitory effect, without decreasing their binding to membranes expressing Ca v 3.3. This suggests that the poly-unsaturated alkyl chain of lipids would be mostly important for their binding whereas the amide and hydroxyl groups would mediate current inhibition. Accordingly, both NADA and NA-5HT strongly occluded TTA-A2 effect but weakly inhibited Ca v 3.3 current whereas saturated lipids (which did not produce inhibition) provided no consistent displacement. We also found that the Hill slope number 1 9 (n Hill ) in these binding assays were high (ranged from 1.5 to 2.4) for NATau, NAGly, NASer and NAEA, especially for NAEA (n Hill = 2.4), whereas the n Hill for NA-5HT and NADA were more typical of competitive displacement curves (n Hill between 1.1 and 1.3). These result might indicate lipid degradation because in these binding experiments we did not use a fatty acid amide hydrolase (FAAH, the main enzyme metabolizing NAEA and others NArachidonoyl-conjugates (Huang et al., 2001; Saghatelian et al., 2006; Saghatelian et al., 2004) ) inhibitor and this enzyme is known to be very active even in crude membrane extracts (Childers et al., 1994; Deutsch and Chin, 1993; Pinto et al., 1994) . For instance, displacement of the cannabinoid receptor CB1 agonist [ 3 H]-CP-55940 by NAEA, indicated K i of 2 µM in the absence of the FAAH inhibitor PMSF whereas K i was 12 nM in the presence of PMSF (Pinto et al., 1994) , suggesting NAEA degradation. Interestingly, the same authors showed that the slope of the displacement curve was particularly steep (n Hill > 2) in the absence of PMSF whereas in the presence of PMSF the n Hill was near a value of 1 (Pinto et al., 1994) .
Interestingly, NA-5HT and NADA are inhibitors of FAAH and particularly NA- 5HT (Bisogno et al., 2000; Bisogno et al., 1998) and this FAAH inhibition could account for the strong NA-5HT potency in the binding assay. In addition, it is important to note that in these membrane extracts, the trans-membrane resting potential was likely lost, and the Ca v 3.3 channels might be in a complete inactivated state that was not achieved in electrophysiological experiments, and this could also explain the potency of NA-5HT and NADA in these binding assays.
Because the structurally distinct antagonist, TTA-Q4, was shown to be a positive allosteric modulator of TTA-A2, increasing TTA-Q4 we revealed important NADA and NA-5HT inhibitory effects, as previously described (Gilmore et al., 2012; Ross et al., 2009) . Interestingly, the binding and the potency of anandamide at CB1 and TRPV1 receptors is increased by palmitoyl ethanolamine and oleoyl ethanolamine, which acts as an allosteric modulator of these receptors, a phenomenon called the "entourage" effect (Ben-Shabat et al., 1998; De Petrocellis et al., 2001; Ho et al., 2008) .
It was demonstrated that TTA-A2 had important pharmacological effects including the reduction of absence epilepsy seizures (Reger et al., 2011; Uebele et al., 2009b) and of pain perception (Francois et al., 2013) . In addition, TTA-A2 affected sleep/wake patterns (Kraus et al., 2010; Reger et al., 2011; Uebele et al., 2009a) and displayed anti-psychotic properties (Uslaner et al., 2012) . Similarly, bio-active lipids inhibiting T-currents have been implicated in several functions, including pain perception (Basbaum et al., 2009; Bradshaw and Walker, 2005; Burstein, 2008) , sleep and epilepsy (Chen and Bazan, 2005) . The analogy between invivo effects of TTA-A2 and lipids, suggests, in the light of our results, that many physiological effects of endogenous lipids are supported by T-current inhibition. Furthermore, TTA-A2 and TTA-Q4 could be important pharmacological tools to dissect the involvement of T-current in the physiological effects of endogenous lipids.
MOL #89581
3 0 Recovery from inactivation was measured using two -30 mV depolarizations lasting 450 ms, which were applied from a HP of -80 mV of increasing duration. (F) Effects of 1 and 3 µM NAGly on deactivation kinetics of Ca v 3.3 currents (τ deac ). Currents were elicited by a 28 ms depolarization at -30 mV and deactivation kinetics were measured at repolarization potentials ranging from -130 to -60 mV. (1) Ctrl (1) Ctrl ( (2) TTA-Q4 + NA-5HT (3) Ctrl (1) NAEA (2) NAEA + TTA-Q4 ( Ctrl (1) TTA-Q4 (2) TTA-Q4 + NAEA (3) Ctrl (1) Ctrl ( Figure 5 
